Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:50AM ET
10.78
Dollar change
-0.27
Percentage change
-2.40
%
IndexRUT P/E- EPS (ttm)-3.89 Insider Own55.49% Shs Outstand57.97M Perf Week17.74%
Market Cap630.71M Forward P/E- EPS next Y-3.23 Insider Trans-10.32% Shs Float26.03M Perf Month0.05%
Income-201.59M PEG- EPS next Q-1.20 Inst Own44.62% Short Float40.12% Perf Quarter16.47%
Sales0.68M P/S927.51 EPS this Y-17.60% Inst Trans6.89% Short Ratio12.52 Perf Half Y4.61%
Book/sh-1.26 P/B- EPS next Y30.00% ROA-69.68% Short Interest10.44M Perf Year57.45%
Cash/sh6.52 P/C1.65 EPS next 5Y- ROE-3489.00% 52W Range6.07 - 17.02 Perf YTD18.13%
Dividend Est.- P/FCF- EPS past 5Y-137.06% ROI-55.18% 52W High-36.63% Beta0.63
Dividend TTM- Quick Ratio10.22 Sales past 5Y0.00% Gross Margin-8.80% 52W Low77.82% ATR (14)0.88
Dividend Ex-Date- Current Ratio10.25 EPS Y/Y TTM22.99% Oper. Margin-24532.40% RSI (14)62.52 Volatility12.64% 9.72%
Employees452 Debt/Eq- Sales Y/Y TTM- Profit Margin-29558.80% Recom1.25 Target Price22.71
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-4.23% Payout- Rel Volume0.58 Prev Close11.05
Sales Surprise70.12% EPS Surprise-29.05% Sales Q/Q- EarningsMar 07 BMO Avg Volume834.53K Price10.78
SMA2014.61% SMA5027.35% SMA2002.95% Trades Volume118,798 Change-2.40%
Date Action Analyst Rating Change Price Target Change
Jan-05-24Reiterated Needham Buy $23 → $26
Aug-09-23Initiated H.C. Wainwright Buy $28
May-11-23Upgrade Evercore ISI In-line → Outperform
Mar-13-23Initiated Craig Hallum Buy $21
Oct-21-22Initiated Jefferies Buy $16
May-06-22Downgrade Evercore ISI Outperform → In-line
May-12-21Upgrade Goldman Sell → Neutral $40 → $48
Feb-17-21Initiated BMO Capital Markets Outperform $63
Feb-02-21Initiated Guggenheim Buy $60
Jun-26-20Downgrade Goldman Neutral → Sell $34
Mar-26-24 08:00AM
Mar-08-24 03:05PM
01:57AM
Mar-07-24 01:51PM
01:38PM
08:00AM Loading…
08:00AM
Feb-29-24 08:00AM
Feb-13-24 08:00AM
Jan-31-24 08:00AM
Dec-14-23 08:00AM
Dec-06-23 08:00AM
Nov-28-23 08:00AM
Nov-09-23 09:34AM
08:00AM
Nov-01-23 05:00PM
08:00AM Loading…
Oct-30-23 08:00AM
Oct-25-23 08:01AM
Sep-26-23 08:01AM
Sep-05-23 08:00AM
Aug-21-23 08:00AM
Aug-10-23 08:01AM
Aug-09-23 10:26AM
Aug-07-23 02:34PM
Jul-14-23 04:40PM
Jul-10-23 08:26AM
Jul-07-23 08:38AM
06:52AM
Jun-12-23 08:01AM
Jun-09-23 04:01PM
Jun-01-23 09:55AM
08:00AM Loading…
08:00AM
May-27-23 09:07AM
May-26-23 09:55AM
May-25-23 09:55AM
May-23-23 07:41PM
04:01PM
04:00PM
May-10-23 08:00AM
May-09-23 08:00AM
Apr-12-23 08:00AM
07:07AM
Apr-10-23 06:44AM
Apr-05-23 08:35AM
Apr-04-23 08:00AM
Mar-27-23 09:55AM
Mar-07-23 12:00PM
Feb-28-23 08:00AM
Feb-10-23 08:53AM
07:59AM
Feb-09-23 04:01PM
Jan-28-23 01:58PM
Jan-24-23 09:02AM
Jan-13-23 06:56AM
Jan-08-23 06:00PM
Jan-06-23 05:02AM
Jan-05-23 11:31AM
Jan-04-23 09:17AM
Jan-03-23 04:01PM
Nov-08-22 05:00PM
Nov-03-22 08:30AM
Nov-01-22 08:00AM
Oct-24-22 08:00AM
Oct-23-22 12:01PM
Oct-18-22 08:00AM
Sep-26-22 08:00AM
Sep-07-22 08:15AM
Aug-17-22 09:16AM
Aug-02-22 08:00AM
Jun-01-22 08:15AM
May-25-22 08:00AM
May-24-22 12:15PM
May-17-22 08:01AM
May-11-22 10:54AM
May-10-22 08:00AM
May-04-22 08:01AM
May-03-22 05:40PM
Apr-26-22 08:00AM
Apr-13-22 02:10PM
Apr-01-22 08:01AM
Mar-22-22 08:02AM
Mar-14-22 08:02AM
Mar-01-22 04:04PM
Feb-11-22 08:52PM
Feb-09-22 04:04PM
Nov-23-21 04:00PM
Nov-12-21 04:30PM
Nov-10-21 08:32PM
Nov-08-21 08:00AM
Oct-27-21 09:47PM
Oct-26-21 04:01PM
Oct-24-21 03:30PM
Oct-21-21 08:00AM
Oct-18-21 12:14PM
10:28AM
08:20AM
07:00AM
Oct-11-21 03:55PM
Sep-27-21 03:50PM
08:00AM
Sep-20-21 08:00AM
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Curran TerriePresident and Chief ExecutiveMar 22 '24Sale9.1116,851153,513410,784Mar 26 04:05 PM
TAKEDA PHARMACEUTICAL CO LTD10% OwnerJan 24 '24Sale8.103,703,70329,999,9943,755,583Jan 25 06:13 AM
Henderson MollyCFO and CBOJan 19 '24Sale7.756,30748,90098,698Jan 22 08:22 PM
Henderson MollyCFO and CBONov 20 '23Sale7.242,12715,403103,061Nov 21 04:40 PM
Parikh AsitDirectorNov 08 '23Buy7.802,50019,50055,000Nov 08 07:56 PM
Parikh AsitDirectorNov 07 '23Buy7.764,00031,04052,500Nov 08 07:56 PM
Parikh AsitDirectorNov 06 '23Buy8.041,0008,04048,500Nov 08 07:56 PM
Henderson MollyCFO and CBONov 01 '23Sale8.8812,492110,871105,188Nov 03 04:55 PM
Henderson MollyCFO and CBOJun 02 '23Sale11.411,96022,36868,506Jun 05 06:32 PM
Henderson MollyCFO and CBOMay 22 '23Sale12.872,11027,16570,466May 23 12:15 PM
Nabulsi AzmiChief Operating OfficerApr 11 '23Buy8.2610,00082,60099,567Apr 11 04:05 PM
Parikh AsitDirectorApr 10 '23Buy7.551,0007,55023,500Apr 11 04:05 PM
Curran TerriePresident and Chief ExecutiveApr 06 '23Buy7.8212,919101,025188,290Apr 07 03:19 PM
Henderson MollyCFO and CBOApr 06 '23Sale7.273,43925,00272,576Apr 07 03:18 PM